BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more powerful, efficient, and accessible for all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.
BillionToOne is headquartered at 1035 O’Brien Dr, Menlo Park, CA 94025. BillionToOne’s main phone number is (650) 460-2551.
BillionToOne is listed on the Nasdaq stock exchange under the ticker symbol “BLLN”.
BillionToOne’s initial public offering was on November 6, 2025 at $60 per share.
BillionToOne’s fiscal year ends on December 31.
BillionToOne does not offer a direct stock purchase plan at this time.
BillionToOne does not pay a dividend.
Quarterly and annual reports, as well as other SEC filings, can be accessed here on our Investor Relations website or directly from the SEC at www.sec.gov
BillionToOne’s independent registered public account firm is PricewaterhouseCoopers.
BillionToOne’s transfer agent is Fidelity Stock Transfer. They can be reached at:
Website: Digital.fidelity.com
Email: FSTOperations@fmr.com
Telephone: (833) 500-1036
Regular Mail:
Fidelity Investments
Attn: Fidelity Stock Transfer Solutions
PO Box 770017
Cincinnati, OH 45277
Overnight Mail:
Fidelity Investments
Attn: Fidelity Stock Transfer Solutions
100 Crosby Parkway
Mail Zone KY16
Covington, KY 41015
Registered stockholders should contact Fidelity Stock Transfer in the event of a name change, address update, or if their certificate has been lost or stolen.
If a registered stockholder does not receive notification of the availability of our proxy statement and annual report prior to the Annual Meeting, Fidelity Stock Transfer is the appropriate contact.
Information on BillionToOne’s management team and Board of Directors can be found here.
You can join our Investor Relations email list here.
For investor inquiries, please contact ir@billiontoone.com. You may also submit questions via the “Contact IR” page here.